Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses

针对 SARS-CoV-2 和其他冠状病毒的广泛刺突蛋白茎疫苗平台

• 批准号: 10493412
• 负责人: Gary R Whittaker
• 金额: $ 23.55万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-22 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10493412
• 关键词: 2019-nCoV; ACE2; Antigens; COVID-19 vaccine; Coronavirus; Engineering; Epitopes; Escherichia coli; Goals; Human; Immune response; Immunize; Membrane; Mus; Nature; Proteins; SARS coronavirus; Serology; Structure; Subunit Vaccines; System; Testing; Transgenic Mice; Vaccination; Vaccine Antigen; Vaccine Design; Vaccines; Vesicle; Viral; Virus; base; cost effective; design; flexibility; human coronavirus; innovation; monoclonal antibody production; mouse model; novel; novel coronavirus; novel vaccines; receptor; response; vaccine development; vaccine platform; variants of concern

Project Summary/Abstract We propose to develop a subunit vaccine for SARS-CoV-2, using a structure-based approach targeting conserved and functionally essential domains in the stalk region of the viral spike protein. We expect our vaccine platform to be applicable and effective across a wide range of existing and emerging coronaviruses. As our system is based on expression in E. coli is it expected to be cost–effective, and our stalk-based approach is specifically designed to cover a range of distinct coronaviruses. However, it is important to note that our vaccine platform is highly flexible, with the antigen able to be re-engineered rapidly in the face of a novel coronavirus that may emerge, and for which the vaccine developed in this application is not effective.

项目概要/摘要 我们建议使用基于结构的方法针对 SARS-CoV-2 开发一种亚单位疫苗 我们期待我们的疫苗能够在病毒刺突蛋白的茎区域找到保守且功能必需的结构域。 平台适用于各种现有和新兴的冠状病毒。 系统基于大肠杆菌中的表达，预计具有成本效益，我们基于茎的方法是 专为覆盖一系列不同的冠状病毒而设计，但值得注意的是，我们的疫苗。 平台高度灵活，面对新型冠状病毒，抗原能够快速重新设计 可能会出现这种情况，而本申请中开发的疫苗对此无效。